Global Leukapheresis Market Overview
The Global Leukapheresis Market is anticipated to record a strong double-digit growth rate by 2027, supported by multiple converging trends within healthcare and biotechnology. Factors such as the increasing prevalence of cancer, continuous growth in R&D investments, expanding use of leukopaks in scientific studies, rising demand for personalized therapeutic solutions, and supportive government initiatives are significantly contributing to the market’s expansion. The field of leukapheresis has gained immense importance due to its pivotal role in cancer treatment, stem cell research, immunotherapy development, and advanced cellular therapies.

Key Request a free sample copy or view report summary: https://meditechinsights.com/global-leukapheresis-market/request-sample/

Leukapheresis is a specialized medical procedure used to separate and collect white blood cells from circulating blood. It is widely employed for both therapeutic and research purposes, particularly in the management of leukemia, lymphomas, and other hematological conditions. The process involves withdrawing blood from the patient, passing it through a machine that isolates leukocytes, and returning the remaining components back to the body. This ability to selectively collect specific white blood cell populations makes leukapheresis valuable in immunology, oncology, and regenerative medicine.

Key Factors Shaping the Global Leukapheresis Market
Leukapheresis has established itself as a crucial tool in hematology and immunology, enabling physicians to manage blood-related disorders more effectively. One of the primary drivers of the market is the rising incidence of blood cancers, including leukemia, lymphoma, and multiple myeloma. These conditions often require leukapheresis either for therapeutic reduction of high white blood cell counts or for the preparation of cells for transplantation and further therapeutic applications.
Another major factor contributing to market expansion is the increasing demand for hematopoietic stem cell transplantation. Leukapheresis plays a vital role in harvesting these stem cells, which are essential for treating various malignant and non-malignant disorders. As the number of stem cell transplant procedures continues to rise globally, the demand for leukapheresis machines, kits, and services increases proportionally.
Technological advancements in apheresis devices have also improved efficiency, safety, and patient comfort. More automated and user-friendly systems have contributed to higher adoption rates across hospitals and specialized centers. In addition, increased healthcare spending in developing and developed countries has improved accessibility to advanced blood-processing procedures.
Several innovations further highlight the market’s growth trajectory. For example:
In August 2023, Terumo Blood and Cell Technologies received FDA clearance for the Reveos Automated Whole Blood Processing System, which can process whole blood into components such as platelets in a single cycle, enhancing supply efficiency.
In June 2023, Haemonetics Corporation secured FDA clearance for enhancements to its NexSys PCS® plasma collection system, featuring advanced technology that shortens procedure time and improves output.

The growing aging population, which is more vulnerable to blood disorders and cancers, also significantly contributes to market demand. Leukapheresis is now being used beyond oncology, with emerging applications in autoimmune diseases, organ transplantation, and immunomodulatory therapies. Additionally, increasing awareness about leukapheresis procedures and supportive regulatory frameworks encourage wider adoption. Investments in R&D further strengthen the market, enabling the development of next-generation apheresis technologies and cell-processing systems.

The Expanding Role of Leukapheresis in Cell-Based Therapies
The introduction of advanced cell-based therapies has substantially accelerated demand for leukapheresis. CAR-T cell therapy, in particular, relies heavily on high-quality leukocyte collection, positioning leukapheresis as a foundational component in modern cancer treatment. As global CAR-T therapy approvals increase, the requirement for leukapheresis machines, consumables, and specialized services is expected to rise significantly.
The rising burden of leukemia and other blood cancers continues to reinforce the importance of leukapheresis. In addition, increased use of leukopaks in research laboratories, particularly for immunotherapy and genetic engineering studies, boosts market growth. Continuous innovation in apheresis technologies, such as automation and intelligent control systems, enhances efficiency and improves clinical outcomes.
For example, in March 2023, Haemonetics Corporation received 510(k) clearance for a next-generation software upgrade for the Cell Saver® Elite®+ Autotransfusion System. This update enhances operational efficiency and streamlines workflow, improving overall user experience.

The COVID-19 pandemic further accelerated the adoption of leukapheresis. The virus’s impact on lymphocyte counts highlighted the need for immune-cell-based research, vaccine development, and convalescent plasma therapies. As a result, the demand for leukocyte collection surged during the pandemic, emphasizing the strategic importance of leukapheresis in global health preparedness.
With globalization enabling better access to advanced medical services in emerging economies, more countries are adopting leukapheresis for clinical and research purposes. The shift toward personalized medicine, which requires precise cell isolation and characterization, continues to elevate the value of leukapheresis in modern healthcare.

Key Challenges of the Global Leukapheresis Market
High costs associated with therapeutic leukapheresis and leukopaks present substantial barriers to adoption, particularly in low-income regions.
Shortage of skilled professionals capable of operating advanced apheresis equipment limits service availability.
Limited adoption of therapeutic leukapheresis in some healthcare systems slows market penetration.
High costs associated with cellular immunotherapies further restrict patient access.
Concerns about blood transfusion safety in developing countries pose additional obstacles to market growth.

Regional Analysis: North America Dominates the Market
North America is expected to continue holding the largest market share due to its advanced healthcare infrastructure, rising cancer incidence, strong focus on personalized therapies, and presence of leading industry players. The region benefits from high awareness levels, supportive reimbursement systems, and rapid adoption of cutting-edge medical technologies.
The Asia-Pacific region, however, is projected to record the fastest growth rate during the forecast period. Factors such as growing geriatric populations, increased awareness of leukapheresis services, expanding healthcare investments, and rising prevalence of blood cancers contribute to its accelerated growth trajectory.

Key Drivers
Rising prevalence of cancer
Growing R&D investments
Expanding utilization of leukopaks in research
Increasing demand for personalized medicine
Favorable government initiatives

Key Players
• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• Terumo BCT Inc.
• Miltenyi Biotec
• Fresenius SE & Co. KGaA
• Caltag Medsystems Limited
• Macopharma SA
• Lonza Group
• Charles River Laboratories
• Zen-Bio

Growth Strategies Adopted by Leading Market Players
Companies in the leukapheresis market are employing both organic and inorganic strategies to strengthen their market presence. Collaborations, acquisitions, and new product launches remain essential for expanding capabilities and market reach.
For example:
In September 2023, Fresenius Kabi partnered with Virginia Oncology Associates to supply the Ivenix Infusion System for administering medications to cancer and blood disorder patients.
In June 2022, Terumo Blood and Cell Technologies partnered with GenCure to create a reference manufacturing center to support cell and gene therapy developers.
In May 2022, Fresenius Kabi completed the acquisition of Ivenix, Inc., enhancing its infusion therapy portfolio and strengthening hospital connectivity capabilities.

The global leukapheresis market is expected to continue growing rapidly due to increasing cancer prevalence, expanding research initiatives, rising adoption of personalized therapies, and sustained innovation among leading industry players.

Get Free Sample Report: https://meditechinsights.com/global-leukapheresis-market/request-sample/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.